Inve India ▾

Emcure Pharmaceuticals share price & results

Emcure Pharmaceuticals Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Pune-based pharma firm: branded generics, biosimilars & injectables across India, EU, Canada & EM markets

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue2,580 ₹ crore+22.8% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin21.0 %+1.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit292 ₹ crore+35.8% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity21.90 %+2.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin4.35 %−1.7 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)18.35 %−2.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

0 of 7 judged targets kept · 10 open · verdicts reflect calls analysed to Q1 FY27.

Emcure Pharmaceuticals Limited management guidance track record on Inve: 17 targets tracked across analysed earnings calls (0 achieved, 7 missed, 10 open).

TargetOriginal wordingSaidLatest callVerdict
Revenue Growth13% to 14% in FY '26
Call transcript, Q4 FY25 · 22 May 2025		Q4 FY25Q1 FY27:Not addressed as the promise pertains to the completed FY26.
Call transcript, Q1 FY27 · 6 Aug 2026		Ghosted
Net DebtNet Cash by March 2026
Call transcript, Q3 FY25 · 6 Feb 2025		Q3 FY25Q1 FY27:Net debt increased to ₹1,103 cr. Management expects a temporary rise in Q2 due to M&A payouts, but reiterated the goal to be net cash by end of FY28.
Call transcript, Q1 FY27 · 6 Aug 2026		On Track

Source: Inve Guidance Tracker for Emcure Pharmaceuticals Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

7 of Emcure Pharmaceuticals Limited's 17 targets were missed. See which ones, and which are quietly gone. The 2 above are the free sample; 15 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,875.2 +5.34% · +₹95

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +38.2% 1Y

₹1.4k₹1.6k₹1.8k₹2.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 11 Nov 2025Q3 FY26 — 4 Feb 2026Q4 FY26 — 5 May 2026Q1 FY27 — 6 Aug 2026

1Y: ₹1,357.3 on 24 Oct 2025 → ₹1,875.2. High ₹2,009.6 (12 Aug 2026), low ₹1,318.9 (31 Oct 2025).

Previous close
₹1,780.2
Market cap
₹35.6k Cr
52-week range
₹1,318.9 – ₹2,009.6
One year
+39.02%
Price to earnings (TTM to Jun 2026)
34.57×
Return on equity (TTM to Jun 2026)
21.90%

Overview

Symbol
NSE:EMCURE
Exchange
NSE
Currency
INR

What Emcure Pharmaceuticals Limited does

Based on the company's own presentations, annual report and earnings calls.

Emcure Pharmaceuticals develops, manufactures and markets branded generics, complex injectables, biosimilars and vaccines across four therapeutic-led businesses: India (Domestic), Emerging Markets, Europe and Canada. It earns primarily by selling branded prescription and OTC medicines through its own field force in India and via subsidiaries/distribution partners abroad, supplemented by in-licensing deals with global majors (Sanofi, Novo Nordisk, Roche) for select brands and by developing first-in-class/first-in-India molecules such as biosimilar Tenecteplase and Peg-Asparaginase. Its subsidiaries Gennova Biopharmaceuticals (biologics/mRNA vaccines), Zuventus Healthcare (domestic branded generics, now fully consolidated) and Emcutix Biopharmaceuticals (dermatology) extend the core business into adjacent categories.

Segments

  • Domestic (India)
  • Emerging Markets (EM)
  • Europe (EU)
  • Canada (CA)
Rank in Indian Pharmaceutical Market (IPM)
#14 largest player
IPM rank in Gynecology
#2
Top-brand strength
19 of top 20 brands rank among top 3 in their therapeutic segment
Manufacturing locations (India)
Bhosari, Hinjawadi, Kurkumbh, Jammu, Sanand, Sikkim, Bangalore, Pimpri — spanning API, oral solid, injectable and biologics facilities
Regulatory approvals
Facilities inspected and approved by USFDA, EU-EMA, UK-MHRA and WHO
Products launched in Canada
~110 launched, with 50+ more awaiting approval
Founded 1981Headquarters Pune, Maharashtra, India Company website

How the price took the results

close before → close after

Q1 FY27
−1.1%
6 Aug
Q4 FY26
−5.7%
5 May
Q3 FY26
+1.9%
4 Feb
Q2 FY26
−4.0%
11 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Emcure Pharmaceuticals Limited

Free account: one company. Everything above stays public.

Write why you follow Emcure Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Emcure Pharmaceuticals Limited

Guides on how to read this kind of business and the numbers that matter.